I hear ya, disappointing that he name dropped Roche and Regeneron and gave us no love.

Let's hope this is just the first seed planted and we see more coverage, but still, despite the brevity of the mention, millions of people could read this article.

I'd rather this than the Wall Street Journal fiasco which was tons of mentioning CytoDyn, but with the intent to mock IMO. Context matters too and the Times article was serious in tone and overall a good piece of journalism.